-
公开(公告)号：EP3321278B1
公开(公告)日：2019-01-09
申请号：EP17208140.8
申请日：2014-11-10
申请人： KeyBioscience AG
IPC分类号： C07K14/585 , A61K38/23
-
公开(公告)号：EP3357540A1
公开(公告)日：2018-08-08
申请号：EP18161594.9
申请日：2012-11-02
申请人： KeyBioscience AG
CPC分类号： C07K14/585 , A61K31/155 , A61K31/64 , A61K38/23 , A61K38/26 , A61K38/28 , A61K2300/00
摘要： A pharmaceutical co-formulation comprising a calcitonin mimetic and an insulin sensitiser, and its use in the treatment type I diabetes, type II diabetes or a metabolic syndrome, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
-
公开(公告)号：EP3095484B1
公开(公告)日：2018-05-02
申请号：EP16174260.6
申请日：2012-11-02
申请人： KeyBioscience AG
CPC分类号： C07K14/585 , A61K31/155 , A61K31/64 , A61K38/23 , A61K38/26 , A61K38/28 , A61K2300/00
摘要： Use of a peptide having SEQ ID NO: 18 for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
-
公开(公告)号：EP2806886B1
公开(公告)日：2017-03-01
申请号：EP13700911.4
申请日：2013-01-22
申请人： Novaliq GmbH
发明人： GÜNTHER, Bernhard , THEISINGER, Bastian , THEISINGER, Sonja , SCHERER, Dieter , WILSON, Clive , PETTIGREW, Anthony , HÜTTIG, Annette
CPC分类号： A61K47/06 , A61K9/0019 , A61K9/0048 , A61K38/23 , A61K38/28 , A61K38/385 , A61K38/4826 , A61K47/24 , C12Y304/21001
摘要： The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.
-
55.发明公开POLYETHYLENE GLYCOL BASED PRODRUG OF ADRENOMEDULLIN AND USE THEREOF 有权ADRENOMEDULLIN-PRODRUG AUF POLYETHYLINGLYKOLBASIS UND VERWENDUNG DAVON
公开(公告)号：EP3075395A1
公开(公告)日：2016-10-05
申请号：EP15192265.5
申请日：2012-10-30
发明人： FLAMME, Ingo , KÖBBERLING, Johannes , LERCHEN, Hans-Georg , GRIEBENOW, Nils , SCHOHE-LOOP, Rudolf , WITTROCK, Sven , KÖLLNBERGER, Maria , WUNDER, Frank , REDLICH, Gordon , KNORR, Andreas , MARLEY, July , PRITCHARD, Iain
CPC分类号： C07K5/06017 , A61K9/007 , A61K38/22 , A61K45/06 , A61K47/60 , C07K5/02 , C07K5/06078 , C07K14/575
摘要： The invention relates medicaments comprising novel polyethylene glycol (PEG) based prodrugs of Adrenomedullin, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation, its use for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, to specific PEG-adrenomedullin prodrugs and its synthesis intermediates.
摘要翻译： 本发明涉及包含新型聚乙二醇（PEG）基于前体药物的肾上腺髓质素或其盐之一，其溶剂合物或其盐的溶剂合物与惰性无毒药学上合适的赋形剂组合的药物，其中药物为药物形式 用于吸入，其用于治疗和/或预防特定PEG-肾上腺髓质素前体药物及其合成中间体的疾病，特别是心血管，水肿和/或炎症性疾病的疾病。
-
56.发明公开METHOD AND COMPOSITION FOR SYNCHRONIZING TIME OF INSEMINATION IN GILTS 审中-公开新泽西州ZUSAMMENSETZUNG ZUR SYNCHRONISIERUNG DER BEFRUCHTUNGSZEIT JUNGSAUEN VERFAHREN
公开(公告)号：EP3074031A1
公开(公告)日：2016-10-05
申请号：EP14865320.7
申请日：2014-11-26
CPC分类号： A61K38/09 , A01K29/005 , A61D17/002 , A61D19/02 , A61K9/0034 , A61K9/0056 , A61K31/575 , A61K47/02 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/38
摘要： Methods and compositions for synchronizing the time of insemination in gilts are provided. More particularly, methods and compositions for synchronizing the time of insemination in gilts using a gonadotropin-releasing hormone and a hormone for synchronizing estrus are provided.
摘要翻译： 提供了在后备母猪中同步授精时间的方法和组合物。 更具体地，提供了使用促性腺激素释放激素和用于同步发情的激素来同步授精后备时间的方法和组合物。
-
57.发明公开ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15 有权AUF DASOSTEOKLASTENABHÄNGIGE蛋白SIGLEC-15 GERICHTETERANTIKÖRPER
公开(公告)号：EP2907826A1
公开(公告)日：2015-08-19
申请号：EP15161779.2
申请日：2008-10-08
发明人： Hiruma, Yoshiharu , Tsuda, Eisuke
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , A61K31/122 , A61K31/352 , A61K31/565 , A61K31/593 , A61K31/663 , A61K38/23 , A61K45/00 , A61P19/08 , A61P19/10 , C12N5/10 , C12P21/08
CPC分类号： C07K16/2851 , A61K31/593 , A61K31/663 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Provision of a cDNA comprising a polynucleotide sequence which encodes a heavy chain and a light chain of an antibody which binds a polypeptide (Siglec-15) and inhibits osteoclast formation and/or osteoclastic bone resorption, a vector comprising the cDNA and a eukaryotic cell transformed with the vector.
摘要翻译： 提供包含编码结合多肽（Siglec-15）并抑制破骨细胞形成和/或破骨细胞骨吸收的抗体的重链和轻链的多核苷酸序列的cDNA，包含cDNA和真核细胞转化的载体 与矢量。
-
公开(公告)号：EP2773365A4
公开(公告)日：2015-05-20
申请号：EP12846423
申请日：2012-11-02
申请人： KEYBIOSCIENCE AG
CPC分类号： C07K14/585 , A61K38/23
摘要： Use of a peptide having SEQ ID NO: 18 for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
-
公开(公告)号：EP1265626B1
公开(公告)日：2014-09-10
申请号：EP01922399.9
申请日：2001-03-14
CPC分类号： C07K16/244 , A61K38/225 , A61K2039/505 , C07K16/2842 , C07K16/286
-
60.发明公开
公开(公告)号：EP2762150A1
公开(公告)日：2014-08-06
申请号：EP14159411.9
申请日：2010-03-10
摘要： Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating insulin resistance, and for reducing serum glucose levels.
摘要翻译： 胰岛淀粉样多肽以外的降钙素家族成员，特别是降钙素本身，可有效治疗I型糖尿病，II型糖尿病或代谢综合征，以减轻胰岛素抵抗和降低血清葡萄糖水平。
-
-
-
-
-
-
-
-
-
搜索结果
313 条记录 (耗时 0.028 秒)
